The company offers a range of advanced imaging services including MRI, CT and PET scans, as well as routine diagnostic and screening imaging services like X-ray, ultrasound and mammography. Lumexa set a company record by opening nine de novo centers in 2025, demonstrating aggressive expansion and capitalizing on secular shifts toward outpatient imaging.
Cyborg Score Rationale
Lumexa reported preliminary 2025 Adjusted EBITDA of $229.0M with higher advanced imaging volumes and strong PET growth, while system-wide total procedures reached 3,972,228 in 2025 with advanced procedures and PET volumes growing faster than overall volume. Recent IPO success and institutional investor interest provide capital for continued de novo expansion.
Top Insights
Record de novo expansion in 2025 with nine new centers, demonstrating execution capability and scalable business model